The Technical Analyst
ARK Genomic Revolution [ARKG]
Exchange: ETF
ARK Genomic Revolution Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.92% $23.97
America/New_York / 1 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 653.83 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 69.00 mill |
| Avg Daily Volume: | 2.42 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -6.11 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE -6.11 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 23.00 - 24.94 ( +/- 4.04%) |
| ATR Model: 14 days |
Forecast:
16:00 - $23.97
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $23.97
Forecast 2: 16:00 - $23.97
Forecast 3: 16:00 - $23.97
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $23.97 (2.92% ) |
| Volume | 5.55 mill |
| Avg. Vol. | 2.42 mill |
| % of Avg. Vol | 229.96 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ARKG
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ARKG
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
Latest News
2024-04-22 05:43:00 - The Motley Fool
3 Cathie Wood ETFs Just Hit 4-Month Lows. Are They Worth Buying Now?
There are better ways to approach innovation than the Ark Innovation ETF. The ARK Space Exploration & Innovation ETF is a balanced bet.
2024-04-04 08:01:07 - Zacks Investment Research
Time to Tap Healthcare ETFs on Nvidia's AI Ambition?
At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.
2024-03-25 05:22:18 - Seeking Alpha
ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons
ARK Genomic Revolution ETF warrants a hold rating due to multiple roadblocks preventing solid returns, including underdeveloped technology, legal hurdles, and unresolved ethical dilemmas. ARKG has a relatively high expense ratio with no dividend yield, and its performance has significantly underperformed the S&P 500 Index. The fund's holdings are concentrated in the healthcare sector, with little overlap with other peer genomics-related funds.
2024-03-25 04:50:00 - The Motley Fool
Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?
Cathie Wood's Ark Genomic Innovation ETF has exited its position in Pfizer. Wood is likely disappointed with Pfizer's stock performance and its obesity drug setbacks.
2024-03-19 14:45:52 - InvestorPlace
3 Biotech ETFs Overdue for a Bounce
Growth-focused investors may wish to set their sights on the hard-hit biotech stocks scene as rates begin to retreat, negative momentum settles and the industry catches a bit of a break for once. Of course, to get a higher chance at outsized gains, one must also have a high risk tolerance and a long-enough investment horizon.
2023-12-27 09:01:12 - Zacks Investment Research
5 Best ETF Areas of Last Week
Wall Street was upbeat last week.The optimism surrounding the likely Fed rate cuts in 2024 aided the rally in the market, barring some occasional dips.
2023-12-18 11:50:55 - ETF Trends
VIDEO: ETF of the Week: ARK Genomic Revolution ETF (ARKG)
On this episode of the “ETF of the Week” podcast, Tom Lydon discussed the ARK Genomic Revolution ETF (ARKG) with Chuck Jaffe of “Money Life.” The pair talked about several topics regarding the fund to give investors a deeper understanding of the ETF overall.
2023-12-14 14:17:05 - Zacks Investment Research
Sector ETFs to Gain as Fed Stays Put, Sees Deeper Rate Cuts in 2024
The Federal Reserve held its benchmark interest rate steady at a range of 5.25%-5.50% on Dec 13. However, the Fed hinted at three 25-bp rate cuts next year.
2023-12-14 14:04:50 - ETF Trends
ETF of the Week: ARK Genomic Revolution ETF (ARKG)
VettaFi's vice chairman Tom Lydon discussed the ARK Genomic Revolution ETF (ARKG) on this week's “ETF of the Week” podcast with Chuck Jaffe of “Money Life.” For more news, information, and analysis, visit VettaFi | ETF Trends.
2023-11-30 07:45:00 - The Motley Fool
1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years
Cathie Wood is known for investing in cutting-edge innovators. Her ARK Genomic Revolution ETF owns several gene-editing companies, but Prime Medicine might be the best of the bunch.